Oryzon Genomics extends its activity through the creation of a proteomics platform
The biotechnology firm Oryzon genomics, located in the CIDEM-PCB Bioincubator, is opening a new area of activity by creating a proteomics platform aimed at furthering its existing research lines and the search for new therapeutic targets. The company will complement the new platform by using the services of the Parc Científic de Barcelona.
According to the firm’s Director General, Carlos Buesa, “the use of proteomic analysis equipment, an important part of the process of discovering, validating and developing new targets, will enable Oryzon Genomics to combine its potential with that of other company platforms, such as DNA chips and bioinformatic resources”. Oryzon will use the proteomics platform to work on improving tools such as shot-gun proteomics, a new system which, in some cases, enables proteome purification to be avoided. New approaches to protein profiling for the identification of protein disease markers will also be developed.
In order to develop its activity in this field Oryzon Genomics has added a new member to its team, namely, the Director of the Proteomics Unit in CSIC’s Institute of Biomedical Research of Barcelona, Joaquín Abián, a pioneering scientist in the development and application of proteomic techniques in Spain. After a period in which he studied toxic oil syndrome Abián’s interest has shifted to the development of methods for the chemical analysis of high molecular weight bioorganic compounds, such as peptides and proteins.